You are here
Articles
Posted on Wednesday, May 11, 2011 - 3:23pm
Please lend your support to our urgent appeal that NICE recognise the reality of targeted cancer therapies and personalised medicine by...
Posted on Wednesday, May 11, 2011 - 2:50pm
please use one or more of the template versions to send to your MP
You can change the wording depending on how you want to address the issues. The versions are in word format so you should be able to copy and paste...
Posted on Tuesday, May 10, 2011 - 11:48am
Contact your Councillors, MP, MEPs, MSPs, or Northern Ireland, Welsh and London AMs for free
Posted on Friday, May 6, 2011 - 1:28am
Posted on Tuesday, May 3, 2011 - 3:50pm
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib...
Posted on Wednesday, April 27, 2011 - 8:11pm
New Strategies for Chronic Myelogenous Leukemia
Despite the major advances in therapy with the successes of imatinib and second-generation tyrosine kinase inhibitors, there is room for improving the management...
Posted on Thursday, April 21, 2011 - 6:15pm
Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Hagop Kantarjian and Jorge Cortes
MD Anderson Cancer Center,...
Posted on Friday, March 25, 2011 - 4:29pm
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Posted on Friday, March 25, 2011 - 4:24pm
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Posted on Friday, March 25, 2011 - 4:20pm
Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Passing the Baton
Jason Gotlib, MD, MS
September 1, 2010
Posted on Tuesday, January 25, 2011 - 11:45am
Published: 24/01/2011 12:27:29
Scientists at the University of East Anglia have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks.Published today by the journal ...
Posted on Sunday, January 16, 2011 - 6:35pm
BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP
Posting Date: December 11, 2010
BELA: international, multicenter, randomized, open-...
Posted on Sunday, January 16, 2011 - 5:35pm
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
D Bixby and M Talpaz
Division of Hematology and Oncology, Department of Internal Medicine...
Posted on Sunday, January 16, 2011 - 5:31pm
First-Line Dasatinib, Nilotinib Sustain Edge Over Imatinib
Elsevier Global Medical News. 2010 Dec 21,
Posted on Wednesday, December 1, 2010 - 1:05pm
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
Elsevier Global Medical News. 2010 Dec 6, JS MacNeil
- ‹ previous
- 22 of 33
- next ›